MONTREAL, March 10, 2020 /CNW Telbec/ - The topical
analgesic Pliaglis has long been awaited by many doctors and
dermatologists in Canada because
it offers patients an effective alternative to traditional
analgesic creams for relieving pain prior to superficial
dermatological procedures. Effective, simple and easy-to-use
because it can easily be removed after 20 minutes, Pliaglis
delivers a unique concentration of topical anaesthetic agents to
the market. In fact, it contains a higher concentration of
lidocaine than other analgesic creams sold in Canada. It also contains tetracaine, a
powerful analgesic commonly used in cosmetic procedures, such as
laser therapy, intense pulsed light (IPL) therapy or electrolysis.
When used at the recommended dosage, the product is safe, and it is
the only formula with this maximum allowable concentration to be
approved by Heath Canada. Now
available by prescription in Canada, Pliaglis is the only topical analgesic
approved by Health Canada and by the U.S. Food and Drug
Administration (FDA).
Pliaglis delivers powerful pain-killing action and its unique
application method – it is a peel-off cream1 which dries
to form a pliable layer within 20 minutes – allows patients to
benefit from optimum local anaesthesia for pain-free
injections of collagen or dermal filler, hair removal, tattoo
removal, laser therapy, resurfacing and other procedures.
Not only has the effectiveness and the high tolerance of
Pliaglis been demonstrated in clinical trials2, but the
product has been used successfully in medical practices in
Europe, South America and the United States.
74% of patients considering a cosmetic procedure were
concerned about pain3
Pliaglis is different from
the other analgesic creams that patients are required to apply
before a procedure. In addition to the recognized pain-killing
action of lidocaine, the high concentration of tetracaine (7%) in
Pliaglis gives patients and health professionals peace of mind
about the efficacy of its numbing action, which lasts up to nine
hours post-procedure.
The innovative application method improves the treatment
experience
Pliaglis is applied by the health professional
prior to the procedure using a spatula at a dosage of approximately
1.3g per square centimetre of skin. Thanks to "Peel" technology,
the cream dries to form a pliable layer which acts like a medicinal
patch. The lidocaine and tetracaine contained in Pliaglis are
released to the pain receptors and nerve endings of the epidermis
for optimal anaesthetic effect. The layer is peeled off after 30
minutes (in most cases) and the skin is then ready for the
procedure.
Pliaglis has been certified safe by Health Canada and the
product is sold only by prescription. Pliaglis is sold in a 30g
tube at a recommended price of $50
(minimum of three tubes per order).
About Crescita Therapeutics Inc.
Crescita (TSX: CTX) is a publicly traded, Canadian commercial
dermatology company with a manufacturing facility and a portfolio
of non-prescription skincare products and prescription drugs for
the treatment and care of skin conditions and diseases and their
symptoms. Crescita owns multiple proprietary drug delivery
platforms that support the development of patented formulations
that can facilitate the delivery of active drugs into or through
the skin. For more information, please see
www.crescitatherapeutics.com.
|
_______________________________
|
|
1
|
Pliaglis
monograph. CRESCITA Therapeutics Inc., December 4, 2012. Other
topical anaesthetics currently on the market contain lidocaine and
tetracaine in concentrations of 5%.
|
|
2
|
Four clinical
trials in which adults were treated either with Pliaglis or a
placebo.
|
|
3
|
Sarkany, M.,
Limitations of currently used topical anaesthetics in daily
practice. Poster presented to the IMCAS World Congress 2012 as
part of the 14th International Master Course on Ageing
Skin, Paris, France, from January 26 to 29, 2012.
|
SOURCE Crescita Therapeutics Inc.